Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
|Articles|July 1, 2008
- Applied Clinical Trials-07-01-2008
- Volume 0
- Issue 0
Update on Russia Trials
Author(s)Lisa Henderson
A recently released report details the current status of the clinical trials market in Russia.
Advertisement
A recently released report details the current status of the clinical trials market in Russia. According to the Russian CRO Synergy Research Group, the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (alias RosZdravNadzor, RZN) approved 130 new clinical trials in Russia in first quarter 2008; that's four trials less than in the corresponding period last year.
The report noted that the main contribution is still made by multinational, multicenter clinical trials. The share of foreign study sponsors in first quarter 2008 stood at 68% of the total number of clinical trials, and 88 new trials were initiated during this period. To read the report from Synergy Research Group, go to
Articles in this issue
over 18 years ago
Business and People Update July 2008over 18 years ago
July Global Newsover 18 years ago
Where's the Trial Dataover 18 years ago
A Dow Jones for Sitesover 18 years ago
ICREL Assesses EU Trials Directiveover 18 years ago
Remembering Recruitmentover 18 years ago
Joint Lab Venture Targets Chinaover 18 years ago
Benchmarking Sitesover 18 years ago
Metrics Gain Tractionover 18 years ago
Orphan Drug R&D Challenges SponsorsAdvertisement
Related to this article
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
CRIO’s chief innovation officer, Mike Wenger touches on the two ways sites get AI adoption wrong.
CRIO’s Mike Wenger, speaker at this year's SCRS summit, maps how sites are actually deploying AI post-pilot stage.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening the distance between signals, human judgment, and the next best action.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5